A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA
wherein R
1
, R
2
, R
3
and R
4
are as described in the specification.
The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.
[EN] PROCESS FOR THE PREPARATION OF PROCÉDÉ POUR L'ÉLABORATION DE 20090924WO2006081332A1PREDIX PHARMACEUTICALS HOLDING [US], et al2006080325AD1-26AD<br/>[FR] PROCÉDÉ POUR L'ÉLABORATION DE 20090924WO2006081332A1PREDIX PHARMACEUTICALS HOLDING [US], et al2006080325AD1-26AD
申请人:ESTEVE LABOR DR
公开号:WO2009115393A1
公开(公告)日:2009-09-24
The invention relates to a process for preparing N-(1-10 phenylethyl)anilines, salts, and solvates thereof, to novel intermediates, and to the use of the intermediates in the preparation of serotonin 5-HT6 antagonists.
Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists
申请人:Laboratorios Del. Dr. Esteve, S.A.
公开号:EP2103596A1
公开(公告)日:2009-09-23
The invention relates to a process for preparing N-(1-phenylethyl)anilines, salts, and solvates thereof, to novel intermediates, and to the use of the intermediates in the preparation of serotonin 5-HT6 antagonists.